Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Succeeds In Changing EMA Ruling On Avastin

This article was originally published in The Pink Sheet Daily

Executive Summary

The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.
Advertisement

Related Content

Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
Avastin Hearing's Deadline For Written Submissions Is Indefinitely Delayed
Genentech Asks A Lot From Avastin Hearing
Genentech Asks A Lot From Avastin Hearing
Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim

Topics

Advertisement
UsernamePublicRestriction

Register

PS072117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel